Loading...
Loading...
OLMA| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.4M |
| Gross Profit | -0.4M |
| Operating Expense | 29.6M |
| Operating I/L | -29.6M |
| Other Income/Expense | 1.3M |
| Interest Income | 1.3M |
| Pretax | -28.3M |
| Income Tax Expense | -1.3M |
| Net Income/Loss | -27.0M |
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of therapies for women's cancers. Its primary focus is on the development of OP-1250, a promising estrogen receptor antagonist and selective ER degrader, currently undergoing Phase 1/2 clinical trials for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.
